It takes a specialist like Zurex Pharma to overcome the scientific and technical barriers to improved skin antisepsis – a critical component in the prevention of Surgical Site Infections (SSIs).   

Board of Directors

​

Frederick A. Robertson, M.D.

Chairman

Thomas V. Ressemann

Independent Director

Michael Liang, Ph.D.

Partner, Baird Capital

​

Robert B. Truitt

President and CEO, Ash

Access Technology

Scientific Advisory Board

​

Dr. Scott Anseth

Surgeon, Twin Cities Orthopedics

Dr. Charles E. Edmiston, Jr. Ph.D

Infection Prevention

​

Dr. Andrew Mulder

Surgeon, St. Cloud Orthopedics

​

Maureen Spencer, M.Ed, RN, CIC, FAPIC

Infection Prevention

​

Mayumi Verona, BSN, RN, CNOR

Dignity Health

Management

​

Paul Vajgrt

CEO

​

Andrew Morgan R.Ph.

Executive Vice President,

Regulatory Affairs

and Clinical

​

Alex M. Kasper

Chief Financial Officer